Jump to content
Sign in to follow this  


Recommended Posts

FDA has accepted the supplemental Biologics License Application (sBLA) for Tecentriq in combination with chemotherapy for the first-line treatment of people with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. https://www.gene.com/media/press-releases/14773/2019-01-16/fda-accepts-genentechs-supplemental-biol 

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this